ISTANBUL - Reuters
The Eczacıbaşı-Monrol venture is set to acquire nuclear medicines firm Capintec.
Turkey’s nuclear medicine company Eczacıbaşı-Monrol, a subsidiary of Eczacıbaşı Pharmaceutical and Industrial Investment, announced Nov. 16 that it had reached an agreement to buy the whole of U.S. firm Capintec Inc., a manufacturer of nuclear medicine instrumentation.
No further details on the deal were immediately available.
The Delaware-based Capintec is a leading worldwide supplier of energy measurement products and services. Eczacıbaşı Pharmaceuticals have a 50 percent stake in Eczacıbaşı-Monrol, which is the market leader in radiopharmasotics production.
“Acquiring Capintec, which is the most renowned brand in its field in the world, following the acquisition of Mal-Image, which is developing new equipment, chemicals, radiopharmasotics and radiation-proof equipments in nuclear medicine, has a big importance in achieving our goals,” said Erdal Karamercan, the chief executive of Eczacıbaşı Holding.
Eczacıbaşı-Monrol acquired Mol-Image last year.
All high technology products, technical infrastructure and
know-how from Mol-Image will be transferred to Capintec, Karamercan said.
The innovative equipment produced by both companies will be put on world markets using the distribution channels of Eczacıbaşı-Monrol, he added.
Eczacıbaşı-Monrol currently has seven production facilities in Turkey and four abroad. The company plans to open two new facilities in Bulgaria and Poland in 2013.
Eczacıbaşı’s Girişim Marketing acquired Ataman Group, a local wet wipe producer, for 56.3 million Turkish Liras, the company had announced a day eralier.
Eczacıbaşı Girişim paid 45 million liras for Ataman Ecza ve Itriyat Deposu and 11.23 million liras for Ataman İlaç Kozmetik Kimya, according to a statement Eczacıbaşı Girişim made to the Istanbul Stock Exchange (İMKB).